72/100 B+ · Elevated risk
No major risk flags in public sources TraceComp due-diligence verdict — sanctions, screening, insolvency, control & financial signals combined.

✅ No sanctions, screening, insolvency or control red flags found in the public sources we cover. (Absence of a flag is not a guarantee — see methodology.)

Unity Biotechnology, Inc.

Active Company 📍 South San Francisco, Ca Chemicals & pharmaceuticals

Company · RC 0001463361

B+

Overview

Unity Biotechnology, Inc. is a company registered in South San Francisco, Ca, United States. The company operates in the chemicals & pharmaceuticals sector. Its TraceComp score of 72 (B+) indicates moderate risk with some areas to watch.

Company Information

Registration Number
0001463361
Legal Form
Company
Address
South San Francisco, Ca

Financial Profile

Latest filed accounts: FY 2024

Revenue (2024) 0 USD
Net Income -25,990,000 USD
Total Assets 37,662,000 USD
Altman Z -1.91 distress

Multi-year financials & ratios

1 year of filed accounts on file — full balance sheets, current ratio, debt-to-equity, net margin and the Altman-Z distress trend.

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Officers & Management

No officers on record.

Research Output

Active research organization. 59 publications · 17,348 citations · h-index 49 in the global scholarly record (OpenAlex — 82.9M papers). Top fields by publication volume: Medicine (48%) · Immunology and Microbiology (18%) · Biochemistry, Genetics and Molecular Biology (15%).

See full research profile — top researchers & publications →

Source: OpenAlex (CC0). Objective publication & citation counts.

Patent Portfolio

Active patent holder. 41 patents · 41 active · 41 granted in the USPTO/EPO record.

See full patent portfolio — most-cited inventions & inventors →

Source: USPTO / EPO open patent data. Objective bibliographic counts.

Risk Signals

No adverse legal events have been recorded for this company.

  • Net loss reported in FY 2024
  • Altman Z-Score in the distress zone — elevated insolvency risk on the model

Data Sources & Freshness

Data sourced from: bulk register.